• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

药物洗脱冠状动脉支架——关注改善患者预后。

Drug-eluting coronary stents - focus on improved patient outcomes.

作者信息

Jaffery Zehra, Prasad Amit, Lee John H, White Christopher J

机构信息

Department of Cardiovascular Diseases, The John Ochsner Heart and Vascular Institute, Ochsner Clinic Foundation, New Orleans, LA, USA.

出版信息

Patient Relat Outcome Meas. 2011 Jul;2:161-74. doi: 10.2147/PROM.S24796. Epub 2011 Sep 22.

DOI:10.2147/PROM.S24796
PMID:22915977
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3417932/
Abstract

The development of stent has been a major advance in the treatment of obstructive coronary artery disease since the introduction of balloon angioplasty. Subsequently, neointimal hyperplasia within the stent leading to in-stent restenosis emerged as a major obstacle in long-term success of percutaneous coronary intervention. Recent introduction of drug-eluting stents is a major breakthrough to tackle this problem. This review article summarizes stent technology, reviews progress of drug-eluting stents and discusses quality of life, patient satisfaction, and acceptability of percutaneous coronary intervention.

摘要

自球囊血管成形术问世以来,支架的发展一直是阻塞性冠状动脉疾病治疗的一项重大进展。随后,支架内新生内膜增生导致支架内再狭窄成为经皮冠状动脉介入治疗长期成功的主要障碍。近期药物洗脱支架的引入是解决这一问题的重大突破。这篇综述文章总结了支架技术,回顾了药物洗脱支架的进展,并讨论了经皮冠状动脉介入治疗的生活质量、患者满意度和可接受性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a576/3417932/773c41600dc7/prom-2-161f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a576/3417932/cde07938e023/prom-2-161f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a576/3417932/1022c21f0b79/prom-2-161f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a576/3417932/4ac04e061dbd/prom-2-161f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a576/3417932/7c6f698437e4/prom-2-161f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a576/3417932/b9cc7e7b597a/prom-2-161f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a576/3417932/4a22e8660b9c/prom-2-161f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a576/3417932/773c41600dc7/prom-2-161f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a576/3417932/cde07938e023/prom-2-161f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a576/3417932/1022c21f0b79/prom-2-161f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a576/3417932/4ac04e061dbd/prom-2-161f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a576/3417932/7c6f698437e4/prom-2-161f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a576/3417932/b9cc7e7b597a/prom-2-161f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a576/3417932/4a22e8660b9c/prom-2-161f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a576/3417932/773c41600dc7/prom-2-161f7.jpg

相似文献

1
Drug-eluting coronary stents - focus on improved patient outcomes.药物洗脱冠状动脉支架——关注改善患者预后。
Patient Relat Outcome Meas. 2011 Jul;2:161-74. doi: 10.2147/PROM.S24796. Epub 2011 Sep 22.
2
Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.经皮冠状动脉介入治疗的最新进展:药物洗脱支架的演变,聚焦于XIENCE V药物洗脱支架。
Coron Artery Dis. 2010 Jan;21(1):46-56. doi: 10.1097/MCA.0b013e328333f550.
3
INtimal hyPerplasia evAluated by oCT in de novo COROnary lesions treated by drug-eluting balloon and bare-metal stent (IN-PACT CORO): study protocol for a randomized controlled trial.OCT 评价药物涂层球囊与金属裸支架治疗初发冠状动脉病变的内膜增生(IN-PACT CORO):一项随机对照试验的研究方案。
Trials. 2012 May 6;13:55. doi: 10.1186/1745-6215-13-55.
4
5
Drug-eluting stent: a review and update.药物洗脱支架:综述与更新
Vasc Health Risk Manag. 2005;1(4):263-76. doi: 10.2147/vhrm.2005.1.4.263.
6
The combined use of Drug-eluting balloon and Excimer laser for coronary artery Restenosis In-Stent Treatment: The DERIST study.药物洗脱球囊与准分子激光联合用于冠状动脉支架内再狭窄治疗:DERIST研究
Cardiovasc Revasc Med. 2017 Apr-May;18(3):165-168. doi: 10.1016/j.carrev.2016.12.012. Epub 2016 Dec 21.
7
Intravascular imaging analysis of a drug-eluting balloon followed by a bare metal stent compared to a drug-eluting stent for treatment of de novo lesions.药物洗脱球囊治疗后行血管内影像学分析与药物洗脱支架治疗初发病变的比较。
Korean J Intern Med. 2019 Jul;34(4):819-829. doi: 10.3904/kjim.2017.378. Epub 2018 Jul 4.
8
Perspectives of drug-eluting stents: the next revolution.药物洗脱支架的前景:下一场革命。
Am J Cardiovasc Drugs. 2002;2(3):163-72. doi: 10.2165/00129784-200202030-00004.
9
Coronary balloon angioplasty, stents, and scaffolds.冠状动脉球囊血管成形术、支架和支架。
Lancet. 2017 Aug 19;390(10096):781-792. doi: 10.1016/S0140-6736(17)31927-X.
10
Coronary artery stents: Part I. Evolution of percutaneous coronary intervention.冠状动脉支架:第一部分。经皮冠状动脉介入治疗的发展历程
Anesth Analg. 2008 Aug;107(2):552-69. doi: 10.1213/ane.0b013e3181732049.

引用本文的文献

1
Drug-eluting balloon: is it useful?药物洗脱球囊:它有用吗?
Egypt Heart J. 2020 Nov 11;72(1):80. doi: 10.1186/s43044-020-00116-7.
2
The 24-Form Tai Chi Improves Anxiety and Depression and Upregulates miR-17-92 in Coronary Heart Disease Patients After Percutaneous Coronary Intervention.24式太极拳可改善冠心病患者经皮冠状动脉介入治疗后的焦虑和抑郁,并上调miR-17-92水平。
Front Physiol. 2020 Mar 11;11:149. doi: 10.3389/fphys.2020.00149. eCollection 2020.
3
The association of depression following percutanous coronary intervention with adverse cardiovascular events: Protocol for a systematic review and meta-analysis.

本文引用的文献

1
Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial.西罗莫司洗脱支架与紫杉醇洗脱支架随机比较的 5 年临床和血管造影结果:冠状动脉血运重建晚期紫杉醇洗脱支架与西罗莫司洗脱支架试验的结果。
Circulation. 2011 Jun 21;123(24):2819-28, 6 p following 2828. doi: 10.1161/CIRCULATIONAHA.110.004762. Epub 2011 Jun 6.
2
Drug-eluting stents for saphenous vein graft lesions.用于隐静脉移植血管病变的药物洗脱支架
JACC Cardiovasc Interv. 2011 May;4(5):590; author reply 591-3. doi: 10.1016/j.jcin.2011.02.008.
3
经皮冠状动脉介入治疗后抑郁症与不良心血管事件的关联:系统评价与荟萃分析方案
Medicine (Baltimore). 2019 Jan;98(2):e13952. doi: 10.1097/MD.0000000000013952.
4
Role of depression in secondary prevention of Chinese coronary heart disease patients receiving percutaneous coronary intervention.抑郁症在接受经皮冠状动脉介入治疗的中国冠心病患者二级预防中的作用。
PLoS One. 2017 Dec 21;12(12):e0187016. doi: 10.1371/journal.pone.0187016. eCollection 2017.
5
Efficacy and safety of drug-eluting stents in the real world: 8-year follow-up.药物洗脱支架在现实世界中的疗效与安全性:8年随访
Arq Bras Cardiol. 2014 Sep;103(3):174-82. doi: 10.5935/abc.20140110. Epub 2014 Aug 1.
Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
晚期临床结果与佐他莫司和西罗莫司洗脱支架。ENDEAVOR III 试验(美敦力 Endeavor 药物 [ABT-578]洗脱冠状动脉支架系统与 Cypher 西罗莫司洗脱冠状动脉支架系统在初发原生冠状动脉病变中的随机对照试验)的 5 年随访结果。
JACC Cardiovasc Interv. 2011 May;4(5):543-50. doi: 10.1016/j.jcin.2010.12.014.
4
Long-term safety and efficacy of paclitaxel-eluting stents final 5-year analysis from the TAXUS Clinical Trial Program.紫杉醇洗脱支架的长期安全性和有效性:TAXUS 临床试验计划的最终 5 年分析。
JACC Cardiovasc Interv. 2011 May;4(5):530-42. doi: 10.1016/j.jcin.2011.03.005.
5
Effects of optimal medical treatment with or without coronary revascularization on angina and subsequent revascularizations in patients with type 2 diabetes mellitus and stable ischemic heart disease.最佳药物治疗联合或不联合冠状动脉血运重建对 2 型糖尿病合并稳定型缺血性心脏病患者心绞痛及后续血运重建的影响。
Circulation. 2011 Apr 12;123(14):1492-500. doi: 10.1161/CIRCULATIONAHA.110.978247. Epub 2011 Mar 28.
6
Symptom clusters and health-related quality of life in people with chronic stable angina.慢性稳定性心绞痛患者的症状群与健康相关生活质量。
J Adv Nurs. 2011 May;67(5):1000-11. doi: 10.1111/j.1365-2648.2010.05564.x. Epub 2011 Feb 24.
7
The cost-effectiveness of percutaneous coronary intervention as a function of angina severity in patients with stable angina.经皮冠状动脉介入治疗在稳定型心绞痛患者中作为心绞痛严重程度函数的成本效益。
Circ Cardiovasc Qual Outcomes. 2011 Mar;4(2):172-82. doi: 10.1161/CIRCOUTCOMES.110.940502. Epub 2011 Feb 8.
8
Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty).台风(评价使用 Cypher 西罗莫司洗脱冠状动脉支架治疗急性心肌梗死伴球囊血管成形术的试验)的 4 年随访结果。
JACC Cardiovasc Interv. 2011 Jan;4(1):14-23. doi: 10.1016/j.jcin.2010.10.007.
9
Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study.在评价依维莫司洗脱驱动冠状动脉支架在治疗初发原生冠状动脉病变的安全性和有效性的随机对照试验的长期随访中:ENDEAVOR II 研究的 5 年结果。
EuroIntervention. 2010 Nov;6(5):562-7. doi: 10.4244/EIJV6I5A95.
10
Drug eluting coronary artery stents.药物洗脱冠状动脉支架。
Curr Drug Deliv. 2010 Dec;7(5):421-7. doi: 10.2174/156720110793566281.